REG-like proteins immunoglobulin derived proteins, compositions, methods and uses
OwnerMarja Heiskalainventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to at least one novel RELP Ig derived protein or specified portion or variant, including isolated nucleic acids that encode at least one RELP Ig derived protein or specified portion or variant, RELP Ig derived protein or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Claims55
An isolated RELP protein human Ig derived protein or specified portion or variant, comprising a human variable and human constant region, wherein said human Ig derived protein or specified portion or variant specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence, selected from the group consisting of SEQ ID NOS:
- 2, 4, 5, 6, 7, 8, 9, 10 and/or 11.
An RELP protein human Ig derived protein or specified portion or variant according to claim 65, wherein said human Ig derived protein or specified portion or variant binds RELP protein with an affinity of at least 10−9 M.
An RELP protein human Ig derived protein or specified portion or variant according to claim 65, wherein said human Ig derived protein or specified portion or variant binds RELP protein with an affinity of at least 10−11 M.
An RELP protein human Ig derived protein or specified portion or variant, according to claim 65, wherein said human Ig derived protein or specified portion or variant binds with an affinity of at least 10−12 M.
An RELP protein human Ig derived protein or specified portion or variant according to claim 65, wherein said human Ig derived protein or specified portion or variant substantially neutralizes at least one activity of at least one RELP protein.
A method for treating a malignant condition or disease condition in a cell, tissue, organ or animal, comprising
- (a) contacting or administering a selected malignant condition or disease modulating effective amount of at least one RELP protein human Ig derived protein or specified portion or variant according to claim 65 with, or to, said cell, tissue, organ or animal.
A method for treating at least one RELP protein mediated disorder, comprising
- (a) administering an effective amount of a composition or pharmaceutical composition comprising at least one RELP protein human Ig derived protein or specified portion or variant to a cell, tissue, organ, animal or patient in need of such modulation, treatment or therapy;
- and
- (b) further administering, before concurrently, and/or after said administering in (a) above, at least one selected from at least one TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anethetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, a diabetes related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an erythropoietin, a filgrastim, a sargramostim, an immunizing agent, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant, adonepezil, a tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an epinephrine or analog, a domase alpha, or a cytokine, a cytokine antagonist.
An RELP protein human Ig derived protein or specified portion or variant, wherein said human Ig derived protein or specified portion or variant binds RELP protein with an affinity of at least 10−9 M.
Any invention described herein.
Dependencies are inferred from the claim text.